Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focusing on central nervous system (CNS), inflammatory, and cardiometabolic diseases, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat during the event.
The virtual summit is scheduled for October 15-17, 2024, with Reviva's fireside chat taking place on Tuesday, October 15, 2024, at 3:30 p.m. ET. Interested parties can access the event through a provided registration link. This participation underscores Reviva's commitment to engaging with the healthcare investment community and showcasing its progress in developing therapies for unmet medical needs.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata focalizzata su malattie del sistema nervoso centrale (CNS), infiammatorie e cardiometaboliche, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Il fondatore, presidente e CEO della società, Laxminarayan Bhat, Ph.D., parteciperà a un incontro informale durante l'evento.
Il summit virtuale è programmato per il 15-17 Ottobre 2024, con l'incontro informale di Reviva che si svolgerà martedì 15 Ottobre 2024, alle 15:30 ET. Le parti interessate possono accedere all'evento tramite un link di registrazione fornito. Questa partecipazione sottolinea l'impegno di Reviva a interagire con la comunità degli investimenti in sanità e a mostrare i progressi nello sviluppo di terapie per esigenze mediche non soddisfatte.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), una empresa farmacéutica en etapa avanzada centrada en enfermedades del sistema nervioso central (CNS), inflamatorias y cardiometabólicas, ha anunciado su participación en el 2024 Maxim Healthcare Virtual Summit. El fundador, presidente y CEO de la compañía, Laxminarayan Bhat, Ph.D., participará en una charla informal durante el evento.
La cumbre virtual está programada para el 15-17 de octubre de 2024, con la charla informal de Reviva que tendrá lugar el martes 15 de octubre de 2024, a las 3:30 p.m. ET. Las partes interesadas pueden acceder al evento a través de un enlace de registro proporcionado. Esta participación subraya el compromiso de Reviva de interactuar con la comunidad de inversión en atención médica y de mostrar su progreso en el desarrollo de terapias para necesidades médicas insatisfechas.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH)은 중추 신경계 (CNS), 염증 및 심혈관 질환에 중점을 둔 후기 단계 제약 회사로, 2024 Maxim Healthcare Virtual Summit에 참여한다고 발표했습니다. 회사의 창립자이자 사장 겸 CEO인 Laxminarayan Bhat, Ph.D.가 행사 중 대담에 참여할 예정입니다.
가상 서밋은 2024년 10월 15일부터 17일까지 예정되어 있으며, Reviva의 대담은 2024년 10월 15일 화요일, 오후 3:30 ET에 진행됩니다. 관심 있는 분들은 제공된 등록 링크를 통해 행사에 접속할 수 있습니다. 이번 참여는 Reviva가 의료 투자 커뮤니티와의 소통을 강화하고 의료적 요구가 충족되지 않은 치료법 개발의 진전을 보여주기 위한 의지를 강조합니다.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), une entreprise pharmaceutique en phase avancée axée sur les maladies du système nerveux central (CNS), inflammatoires et cardiométaboliques, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Le fondateur, président et CEO de l'entreprise, Laxminarayan Bhat, Ph.D., participera à une discussion informelle lors de l'événement.
Le sommet virtuel est prévu pour le 15-17 octobre 2024, avec la discussion informelle de Reviva se tenant le mardi 15 octobre 2024 à 15h30 ET. Les parties intéressées peuvent accéder à l'événement via un lien d'inscription fourni. Cette participation souligne l'engagement de Reviva à interagir avec la communauté des investissements en santé et à montrer ses progrès dans le développement de thérapies pour des besoins médicaux non satisfaits.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), ein Unternehmen in der späten Phase der pharmazeutischen Entwicklung, das sich auf Erkrankungen des zentralen Nervensystems (CNS), Entzündungen und kardiometabolische Erkrankungen konzentriert, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt gegeben. Der Gründer, Präsident und CEO des Unternehmens, Laxminarayan Bhat, Ph.D., wird während der Veranstaltung an einem informellen Gespräch teilnehmen.
Der virtuelle Gipfel ist für den 15.-17. Oktober 2024 geplant, wobei das informelle Gespräch von Reviva am Dienstag, den 15. Oktober 2024 um 15:30 Uhr ET stattfinden wird. Interessierte Parteien können über einen bereitgestellten Registrierungslink auf die Veranstaltung zugreifen. Diese Teilnahme unterstreicht Revivas Engagement, mit der Gesundheitsinvestmentgemeinschaft zu interagieren und Fortschritte bei der Entwicklung von Therapien für unbefriedigte medizinische Bedürfnisse zu präsentieren.
- None.
- None.
CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually October 15-17, 2024.
2024 Maxim Healthcare Virtual Summit
Format: Fireside chat
Date: Tuesday, October 15, 2024
Time: 3:30 p.m. ET
Location: Virtual
Registration Link: Click Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
When is Reviva Pharmaceuticals (RVPH) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent Reviva Pharmaceuticals (RVPH) at the 2024 Maxim Healthcare Virtual Summit?
What is the format of Reviva Pharmaceuticals' (RVPH) participation in the 2024 Maxim Healthcare Virtual Summit?
What are the main areas of focus for Reviva Pharmaceuticals (RVPH) in drug development?
